Evaluation of three different formats of a neutralizing single chain human antibody against toxin Cn2: Neutralization capacity versus thermodynamic stability

Immunology Letters

Volumn 143, Issue 2, 2012, Pages 152-160

  Quintero Hernández, Veronica ^a   Del Pozo Yauner, Luis ^b   Pedraza Escalona, Martha ^a   Juárez González, Victor R ^a   Alcántara Recillas, Israel ^a   Possani, Lourival D ^a   Becerril, Baltazar ^a  

^a INSTITUTO DE BIOTECNOLOGÍA   (Mexico)

^b INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

Author keywords

Centruroides noxius; Diabody; Fab; ScFv; Thermodynamic stability; Toxin neutralization

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; SCORPION VENOM; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 6009F; TOXIN CN2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; ENVENOMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERMODYNAMICS; THERMOSTABILITY;

ANIMALS; ANTIBODIES, NEUTRALIZING; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MODELS, MOLECULAR; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STABILITY; SCORPION VENOMS; SINGLE-CHAIN ANTIBODIES; THERMODYNAMICS;

EID: 84859101968     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.01.010     Document Type: Article

References (69)

1. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991, 222:581-597.
2. Zhang H., Torkamani A., Jones T.M., Ruiz D.I., Pons J., Lerner R.A. Phenotype-information-phenotype cycle for deconvolution of combinatorial antibody libraries selected against complex systems. PNAS 2011, 108:13456-13461.
3. Smirnov I., Carletti E., Kurkova I., Nachon F., Nicolet Y., Mitkevich V.A., et al. Reactibodies generated by kinetic selection couple chemical reactivity with favorable protein dynamics. PNAS 2011, 108:15954-15959.
4. Loo L., Robinson M.K., Adams G.P. Antibody engineering principles and applications. Cancer J 2008, 14:149-153.
5. Colcher D., Goel A., Pavlinkova G., Beresford G., Booth B., Batra S.K. Effects of genetic engineering on the pharmacokinetics of antibodies. Q J Nucl Med 1999, 43:132-139.
6. Perisic O., Webb P.A., Holliger P., Winter G., Williams R.L. Crystal structure of a diabody, a bivalent antibody fragment. Structure 1994, 2:1217-1226.
7. Holliger P., Brissinck J., Williams R.L., Thielemans K., Winter G. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 1996, 9:299-305.
8. Girgis M.D., Kenanova V., Olafsen T., McCabe K.E., Wu A.M., Tomlinson J.S. Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res 2011, 170:169-178.
9. Foex B.A. Meta-analysis of controlled studies on immunotherapy in severe scorpion envenomation: a commentary. Emerg Med J 2011, 28:915-916.
10. Chippaux J.P., Goyffon M. Epidemiology of scorpionism: a global appraisal. Acta Trop 2008, 107:71-79.
11. Boyer L.V., Theodorou A.A., Berg R.A., Mallie J., Chavez-Mendez A., Garcia-Ubbelohde W., et al. Antivenom for critically ill children with neurotoxicity from scorpion stings. N Engl J Med 2009, 360:2090-2098.
12. Abroug F., Ouanes-Besbes L., ElAtrous S. Antivenom for children with neurotoxicity from scorpion stings. N Engl J Med 2009, 361:631-632.
13. Natu V.S., Kamerkar S.B., Geeta K., Vidya K., Natu V., Sane S., et al. Efficacy of anti-scorpion venom serum over prazosin in the management of severe scorpion envenomation. J Postgrad Med 2010, 56:275-280.
14. Thirunavukkarasu A.B., Chandrasekaran V. Efficacy of anti-scorpion venom serum over prazosin in severe scorpion envenomation: is the current evidence enough?. J Postgrad Med 2011, 57:83-84.
15. Lovrecek D., Tomic S. A century of antivenom. Coll Antropol 2011, 35:249-258.
16. Espino-Solis G.P., Riano-Umbarila L., Becerril B., Possani L.D. Antidotes against venomous animals: state of the art and prospectives. J Proteomics 2009, 72:183-199.
17. Muzard J., Billiald P., Goyffon M., Aubrey N. Recombinant antibodies: a new application in scorpion envenomation. Bull Soc Pathol Exot 2005, 98:383-385.
18. Devaux C., Moreau E., Goyffon M., Rochat H., Billiald P. Construction and functional evaluation of a single-chain antibody fragment that neutralizes toxin AahI from the venom of the scorpion Androctonus australis hector. Eur J Biochem 2001, 268:694-702.
19. Juarez-Gonzalez V.R., Riano-Umbarila L., Quintero-Hernandez V., Olamendi-Portugal T., Ortiz-Leon M., Ortiz E., et al. Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2. J Mol Biol 2005, 346:1287-1297.
20. Riano-Umbarila L., Juarez-Gonzalez V.R., Olamendi-Portugal T., Ortiz-Leon M., Possani L.D., Becerril B. A strategy for the generation of specific human antibodies by directed evolution and phage display. An example of a single-chain antibody fragment that neutralizes a major component of scorpion venom. FEBS J 2005, 272:2591-2601.
21. Quintero-Hernandez V., Juarez-Gonzalez V.R., Ortiz-Leon M., Sanchez R., Possani L.D., Becerril B. The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies. Mol Immunol 2007, 44:1307-1315.
22. +-channel toxins protects against experimental scorpion envenoming. Cell Mol Life Sci 2007, 64:206-218.
23. Riano-Umbarila L., Contreras-Ferrat G., Olamendi-Portugal T., Morelos-Juarez C., Corzo G., Possani L.D., et al. Exploiting cross-reactivity to neutralize two different scorpion venoms with one single chain antibody fragment. J Biol Chem 2011, 286:6143-6151.
24. Ben Abderrazek R., Vincke C., Hmila I., Saerens D., Abidi N., El Ayeb M., et al. Development of Cys38 knock-out and humanized version of NbAahII10 nanobody with improved neutralization of AahII scorpion toxin. Protein Eng Des Sel 2011, 24:727-735.
25. Hmila I., Abdallah R.B., Saerens D., Benlasfar Z., Conrath K., Ayeb M.E., et al. VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. Mol Immunol 2008, 45:3847-3856.
26. Aubrey N., Devaux C., Sizaret P.Y., Rochat H., Goyffon M., Billiald P. Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin. Cell Mol Life Sci 2003, 60:617-628.
27. Aubrey N., Muzard J., Christophe Peter J., Rochat H., Goyffon M., Devaux C., et al. Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments. Toxicon 2004, 43:233-241.
28. Zamudio F., Saavedra R., Martin B.M., Gurrola-Briones G., Herion P., Possani L.D. Amino acid sequence and immunological characterization with monoclonal antibodies of two toxins from the venom of the scorpion Centruroides noxius Hoffmann. Eur J Biochem 1992, 204:281-292.
29. Schiavon E., Sacco T., Cassulini R.R., Gurrola G., Tempia F., Possani L.D., et al. Resurgent current and voltage sensor trapping enhanced activation by a beta-scorpion toxin solely in Nav1.6 channel. Significance in mice Purkinje neurons. J Biol Chem 2006, 281:20326-20337.
30. Carter P., Kelley R.F., Rodrigues M.L., Snedecor B., Covarrubias M., Velligan M.D., et al. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology (N Y) 1992, 10:163-167.
31. Schier R., Marks J.D., Wolf E.J., Apell G., Wong C., McCartney J.E., et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1995, 1:73-81.
32. WHO Progress in the characterization of venoms and standardization of antivenoms 1981, WHO Offset Publication, WHO, Geneva, p 58.
33. Possani L.D., Dent M.A.R., Martin B.M., Maelicke A., Svendsen I. The amino terminal sequence of several toxins from the venom of the Mexican scorpion Centruroides noxius Hoffmann. Carlsberg Res Commun 1981, 46:207-214.
34. Bolen D.W., Santoro M.M. Unfolding free energy changes determined by the linear extrapolation method. 2. Incorporation of delta G degrees N-U values in a thermodynamic cycle. Biochemistry 1988, 27:8069-8074.
35. Whitelegg N.R., Rees A.R. WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng 2000, 13:819-824.
36. Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993, 234:779-815.
37. L packing in antibodies. Protein Eng Des Sel 2010, 23:689-697.
38. Frey D., Huber T., Pluckthun A., Grutter M.G. Structure of the recombinant antibody Fab fragment f3p4. Acta Crystallogr D Biol Crystallogr 2008, 64:636-643.
39. Krissinel E., Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol 2007, 372:774-797.
40. Dundas J., Ouyang Z., Tseng J., Binkowski A., Turpaz Y., Liang J. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res 2006, 34:W116-W118.
41. DeLano W.L. The PyMOL molecular graphics system 2002.
42. Arndt M.A., Krauss J., Rybak S.M. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers. FEBS Lett 2004, 578:257-261.
43. Canul-Tec J.C., Riano-Umbarila L., Rudino-Pinera E., Becerril B., Possani L.D., Torres-Larios A. Structural basis of neutralization of the major toxic component from the scorpion Centruroides noxius Hoffmann by a human-derived single-chain antibody fragment. J Biol Chem 2011, 286:20892-20900.
44. Vaz de Andrade E., Freitas S.M., Ventura M.M., Maranhao A.Q., Brigido M.M. Thermodynamic basis for antibody binding to Z-DNA: comparison of a monoclonal antibody and its recombinant derivatives. Biochim Biophys Acta 2005, 1726:293-301.
45. Rothlisberger D., Honegger A., Pluckthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005, 347:773-789.
46. Holliger P., Wing M., Pound J.D., Bohlen H., Winter G. Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol 1997, 15:632-636.
47. Pluckthun A., Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997, 3:83-105.
48. Iliades P., Dougan D.A., Oddie G.W., Metzger D.W., Hudson P.J., Kortt A.A. Single-chain Fv of anti-idiotype 11-1G10 antibody interacts with antibody NC41 single-chain Fv with a higher affinity than the affinity for the interaction of the parent Fab fragments. J Protein Chem 1998, 17:245-254.
49. Su B., Hrin R., Harvey B.R., Wang Y.J., Ernst R.E., Hampton R.A., et al. Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays. J Immunol Methods 2007, 322:94-103.
50. Townsend S., Finlay W.J., Hearty S., O'Kennedy R. Optimizing recombinant antibody function in SPR immunosensing. The influence of antibody structural format and chip surface chemistry on assay sensitivity. Biosens Bioelectron 2006, 22:268-274.
51. Kikuchi Y., Uno S., Nanami M., Yoshimura Y., Iida S., Fukushima N., et al. Determination of concentration and binding affinity of antibody fragments by use of surface plasmon resonance. J Biosci Bioeng 2005, 100:311-317.
52. Rau D., Kramer K., Hock B. Cloning, functional expression and kinetic characterization of pesticide-selective Fab fragment variants derived by molecular evolution of variable antibody genes. Anal Bioanal Chem 2002, 372:261-267.
53. Cupit P.M., Lorenzen N., Strachan G., Kemp G.J., Secombes C.J., Cunningham C. Neutralisation and binding of VHS virus by monovalent antibody fragments. Virus Res 2001, 81:47-56.
54. Pavlinkova G., Beresford G.W., Booth B.J., Batra S.K., Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J Nucl Med 1999, 40:1536-1546.
55. Torres M., Fernandez-Fuentes N., Fiser A., Casadevall A. The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem 2007, 282:13917-13927.
56. Kortt A.A., Dolezal O., Power B.E., Hudson P.J. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 2001, 18:95-108.
57. Holliger P., Prospero T., Winter G. Diabodies: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993, 90:6444-6448.
58. Atwell J.L., Pearce L.A., Lah M., Gruen L.C., Kortt A.A., Hudson P.J. Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase. Mol Immunol 1996, 33:1301-1312.
59. Sheikholvaezin A., Eriksson D., Ahlstrom K.R., Johansson L., Stigbrand T. Tumor radioimmunolocalization in nude mice by mono- and divalent- single-chain Fv antiplacental alkaline phosphatase antibodies. Cancer Biother Radiopharm 2007, 22:64-72.
60. Honegger A., Malebranche A.D., Rothlisberger D., Pluckthun A. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains. Protein Eng Des Sel 2009, 22:121-134.
61. Nieba L., Honegger A., Krebber C., Pluckthun A. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng 1997, 10:435-444.
62. Kugler M., Stein C., Schwenkert M., Saul D., Vockentanz L., Huber T., et al. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng Des Sel 2009, 22:135-147.
63. H in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry 1998, 37:13120-13127.
64. Garber E., Demarest S.J. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 2007, 355:751-757.
65. Kortt A.A., Malby R.L., Caldwell J.B., Gruen L.C., Ivancic N., Lawrence M.C., et al. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. Eur J Biochem 1994, 221:151-157.
66. Lee Y.C., Boehm M.K., Chester K.A., Begent R.H., Perkins S.J. Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy. J Mol Biol 2002, 320:107-127.
67. Lawrence L.J., Kortt A.A., Iliades P., Tulloch P.A., Hudson P.J. Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments. FEBS Lett 1998, 425:479-484.
68. Narayanan A., Sellers B.D., Jacobson M.P. Energy-based analysis and prediction of the orientation between light- and heavy-chain antibody variable domains. J Mol Biol 2009, 388:941-953.
69. Huang B.C., Foote L.J., Lankford T.K., Davern S.M., McKeown C.K., Kennel S.J. A diabody that dissociates to monomer forms at low concentration: effects on binding activity and tumor targeting. Biochem Biophys Res Commun 2005, 327:999-1005.